Weekly Paclitaxel After Adjuvant FAC Offers Modest, but Clinically Relevant Improvement in Disease-Free Survival in Patients with High-Risk, Node-Negative Breast Cancer

Share this content:
Weekly Paclitaxel After Adjuvant FAC Offers Modest, but Clinically Relevant Improvement in Disease-F
Weekly Paclitaxel After Adjuvant FAC Offers Modest, but Clinically Relevant Improvement in Disease-F
CME

Program Description:

Adjuvant therapy including 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) followed by weekly paclitaxel was associated with a slight but significant improvement in disease-free survival versus FAC alone in patients with high-risk, node-negative breast cancer, according to results of the first efficacy analysis presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.

INTENDED AUDIENCE:

Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.

Activity Objectives:

After participating in this educational activity, participants should be better able to:

  • Evaluate the role of a sequential weekly addition of paclitaxel to cytotoxic agent protocols in patients with high-risk node-negative breast cancer.

  • Identify the hematologic and nonhematologic toxicities associated with FAC and FAC-paclitaxel in high-risk node-negative breast cancer patients.

Click Next to begin the activity.

Page 1 of 4

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs